HIV New Product Introduction Toolkit

Key CHAI Tools and Resources

• Preparing for COVID-19: Recommendations for National HIV Programs: English | French

• Sustaining Critical Advanced HIV Disease (AHD) Service Delivery During COVID-19: French | English

​

• Rapid Implementation of ARV Multi-Month Dispensing during COVID-19

• COVID-19 ART Healthcare Worker Counselling Materials

• Preparing for COVID-19: Mobile Health Considerations

• Preparedness Recommendations for National HIV Testing and Lab Programs

• COVID-19 Evidence and Preparedness Recommendations for Pregnant Women, Infants, and Children

• Checklist of Critical Actions for National HIV Programs: English| French​

PEPFAR, Global Fund, and WHO Guidance

• COP/ROP Temporary Pause FAQ (PEPFAR) *NEW

• Plans for Resumption of PEPFAR COP/ROP 2021 Planning Process *NEW

• Q&A on HIV and viral hepatitis and COVID-19 (WHO)

• APWG COVID-19 Newsflash

• PEPFAR Technical Guidance in the Context of COVID-19 Pandemic *Recently updated

• Global Fund COVID-19 Updates

• Global Fund Health Product Supply Updates

• Global Fund COVID-19 Information note: Considerations for Global Fund support of HIV

• Actions to Take to Ensure Supplies are Available (USAID-GHSCP)

• Disruption in HIV, Hepatitis and STI services due to COVID-19 (WHO)

Community Resources

AfroCAB/CHAI

• AfroCAB/CHAI COVID-19 Community Consultation and Webinar Series 

aidsmap

• European AIDS Treatment Group documents the impact of COVID on HIV services throughout Europe 

CDC Foundation/Project ECHO

• CDC Foundation Advanced HIV Disease Series

CQUIN

• Differentiated Service Delivery & COVID-19

FHI 360

• Strategic Considerations for Mitigating the Impact of COVID-19 on Key-Population-Focused HIV Programs (April 2020)​

HIV i-Base

• U.S. Interim Guidelines on COVID-19 and HIV (March 2020)

• April 2020 HIV Treatment News Bulletin (April 2020)​

IAS ​

• COVID-19 and HIV: What you need to know

• COVID-19 and HIV: Webinar Series

• Resources to support differentiated service delivery during COVID-19

UNAIDS

• The Risks and Benefits of Providing HIV Services during the COVID-19 Pandemic - medRxiv study (April 2021) *New!

• Rights in the time of COVID-19: Lessons from HIV for an effective, community-led response

• What PLHIV need to know about HIV and COVID-19: Brochure | Infographics 

• Maintaining and prioritizing HIV prevention services in the time of COVID-19

• Lessons from HIV prevention for preventing COVID-19 in low-and middle-income countries (April 2020)

• Six concrete measures to support women and girls in all their diversity in the context of the COVID-19 pandemic

• COVID-19 and HIV: Moment, Epidemics, Opportunities -- How to seize the moment to learn, leverage, and build a new way forward for everyone's health and rights 

• Addressing stigma and discrimination in the COVID-19 response 

• COVID-19's impact on HIV treatment less severe than feared 

UNICEF​​

• Sustaining the gains and reimagining the future for children, adolescents and women (July 2020)

Clinical Evidence Resources on COVID-19 and HIV

• Therapeutic Options for COVID-19 Currently Under Investigation (NIH, Ongoing)

• A Trial of LPV/r in Adults Hospitalized with Severe COVID-19 (NEJM, March 2020)

• Systematic Review of the efficacy and safety of ARVs against SARS, MERS, of COVID-19 (JIAS, March 2020)

• COVID-19 in Patients with HIV: Clinical Case Series (Lancet, April 2020)

• Darunavir does not prevent SARS CoV-2 infection in HIV patients (Pharmacological Research, April 2020)

• Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomized, phase 2 trial (Lancet, May 2020)

• Potential effects of disruption to HIV programs in sub-Saharan Africa caused by COVID-19: results from multiple models (WHO, May 2020)

• COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients (Journal of Infectious Disease, May 2020)

• Spanish study raises possibility that old-style tenofovir might protect against COVID-19 (aidsmap, June 2020)

• COVID-19, HIV and TB Webinar - COVID-19 and TPT (Arum Institute, June 2020)

• COVID-19, HIV and TB Webinar - Dr. Mary-Ann Davies, Western Cape Department of Health: Preliminary Analysis of Risk Factors for COVID-19 deaths in the province (Arum Institute, June 2020)

• London study shows people with HIV not at greater risk of severe COVID-19 illness (aidsmap, July 2020)

• COVID-19 affects HIV and tuberculosis care (AAAS Science, July 2020)

• No link between HIV status and coronavirus outcomes in large US study (aidsmap, July 2020)

• Two UK studies find that HIV infection may be a risk factor for dying from COVID-19 (aidsmap, August 2020)

• High prevalence of underlying health conditions explains increased COVID-19 mortality seen in people with HIV in US study (aidsmap, September 2020)

• COVID-19 more prevalent among general vs HIV-positive population, Barcelona study says (AJMC, September 2020)

• Preventive efficacy of tenofovir/emtricitabine against SARS-CoV-2 among PrEP users (Oxford Academy, September 2020)

• Characteristics, comorbidities and outcomes in a multicenter registry of patients with HIV and Coronavirus Disease-19 (Oxford Academy, September 2020)

• US study of HIV-positive people with COVID-19 reports worse outcomes with comorbidities and having a CD4 <200 (i-base, October 2020)

• The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis (Lancet, February 2021) *NEW

• 'Resilient' HIV programmes in African countries have maintained viral suppression during the COVID-19 pandemic (aidsmap, March 2021) *NEW

Global Stakeholder COVID-19 Response Resources